Tribe Capital and Natural Capital led a $50m Series B round in Ashvattha Therapeutics.

Synopsis

Tribe Capital and Natural Capital, a venture capital firms, led a $50m Series B round in Ashvattha Therapeutics, a biotechnology company.

Principals

Ashvattha Therapeutics

Tribe Capital

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (3)

ben shannon

Strategic Advisor at ICR Healthcare

PR Consultant

target

Deal

£ 40 M

Total Value

jeff cleland

CEO at ASHVATTHA THERAPEUTICS

Manager

target

Deal

£ 40 M

Total Value

aman r. patel

Investor Relations at Westwicke

PR Consultant

target

Deals

£ 208 M

Total Value

Bidder Team (1)

arjun sethi

Chief Investment Officer at TRIBE CAPITAL

Investor

bidder

Deal

£ 40 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy